Tag: PCSK9

Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease

Coronary/Structural Heart by 0 comments

Treatment of Non-Human Primates with Clinical Candidate, VERVE-101, Led to Durable Reductions of PCSK9 Protein and Low-density Lipoprotein Cholesterol Comprehensive Off-Target Editing Analysis Using Industry Leading Methods, ONE-seq and Digenome-seq Showed No Off-Target Editing Across 244 Potential Sites in Human Liver […]

Continue Reading →

Promising new data for Ionis’ antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020

Coronary/Structural Heart by 0 comments

– Single doses resulted in potent, dose-dependent PCSK9 reductions of up to >90%, demonstrating best-in-class potential for the treatment of patients with high cholesterol at risk of cardiovascular disease CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new […]

Continue Reading →

Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

Coronary/Structural Heart by 0 comments

New Registry, cvMOBIUS, Will Assess Lipid Therapies and Five-Year Cardiovascular Outcomes in 8,500 High-Risk Patients With a Recent Atherosclerotic Cardiovascular Disease Event THOUSAND OAKS, Calif., Nov. 15, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) today […]

Continue Reading →